Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 881

Sort by

Sort Order Select

Journal Articles

Superior Therapy Response Predictions for Patients with Myelodysplastic Syndrome (MDS) Using Cellworks Singula™: Mycare-020-02

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-142214

Published: 2020

Journal Articles

Chromosomal Abnormalities in MDS Are Linked to Dysregulation of CDC20 and CEP55 Genes

Mayara Magna de Lima Melo, Daniela de Paula Borges, M.Sc., Antônio Wesley Araújo Dos Santos, Postgraduate student, Gabrielle Melo Cavalcante, M.Sc., Leticia Rodrigues Sampaio, Student, Roberta Taiane Germano Oliveira, M.Sc., Silvia Maria Meira Magalhães, MD PhD, Ronald Feitosa Pinheiro, MD PhD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-143249

Published: 2020

Journal Articles

Monoclonal Protein Response Trajectory and Survival in Newly Diagnosed Multiple Myeloma: A Retrospective Cohort Study

Jayce Bi, BSc, Pascal Lambert, M.Sc., Brett L. Houston, MD, Leonard A. Minuk, MDFRCPC, Vi Dao, MD, Rami Kotb, MD, Donald S. Houston, MD PhD, Ryan Zarychanski, MDMSc,FRCPC, Emily Rimmer, MDFRCPC

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-142271

Published: 2020

Journal Articles

Efficient, Non-Viral and Reproducible Protocol for Stable Knockdown of Genes in Mantle Cell Lymphoma Cell Lines

Simone Valentin Hansen, M.Sc., Mia Koldby Blum, B.Sc., Niels Abildgaard, MD, Charlotte Guldborg Nyvold, MSc, PhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-142353

Published: 2020

Journal Articles

Comparative Analysis for Differential Drug Response between Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) and T-Cell Acute Lymphoblastic Leukemia (T-ALL) Patients Using the Cellworks Omics Biology Model (CBM): Mycare-021-03

Scott Howard, MD, Ansu Kumar, M.Sc., Anusha Pampana, M.Sc., Yashaswini S Ullal, M.Tech., Anuj Tyagi, M.Sc., Deepak Anil Lala, B.Tech., Pallavi Kumari, M.Sc., Vishwas Joseph, M.Sc., Karthik Sundara Raju, M.Sc., Veena Balakrishnan, M.Sc., Nirjhar Mundkur, B.S., Michele Dundas Macpherson, B.A.Sc., Prashant Ramachandran Nair, B.Tech., Shweta Kapoor, M.Sc.

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139997

Published: 2020

Journal Articles

High MYC Protein Expression in MDS Is Associated with Early Transformation to AML

Seongseok Yun, MDPhD, David Gajzer, MD, Najla Al Ali, M.Sc, Nicole D. Vincelette, PhD, Pukhraz Basra, MBBS, Chetasi Talati, MD, Andrew T. Kuykendall, MD, Eric Padron, MD, Kendra Sweet, MD, Rami S. Komrokji, MD, Jeffrey E. Lancet, MD, David A. Sallman, MD, Ling Zhang, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-137116

Published: 2020

Journal Articles

Detection of M-Protein in Acetonitrile Precipitates of Serum Using MALDI-TOF Mass Spectrometry: A Novel Methodology

Nikita Mehra, MDDM, Gopal Gopisetty, PhD, Jayavelu S, M.Sc, Arivazhagan Rajamanickam, PhD, Shirley Sundersingh, MD PhD, Jayachandran PK, MD MRCP, DM, Parathan Karunakaran, MD, Krishnarathinam Kannan, MD DM, Venkatraman Radhakrishnan, MD DM, Tenali Gnana Sagar, MD DM, Thangarajan Rajkumar, MD, D.M., PhD, D.Sc., FAMS

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-141301

Published: 2020

Journal Articles

Impact of Age, Comorbidity, and Polypharmacy on Treatment and Survival for Aggressive Non-Hodgkin Lymphoma

Laura Tapley, MD, Pamela Skrabek, MD, Pascal Lambert, M.Sc., Jenniebie Bravo, M.Sc., Kathleen Decker, PhD, Piotr Czaykowski, MD, Donna Turner, MD, Phil St. John, MD, David Dawe, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-142591

Published: 2020

Journal Articles

SF3B1 Splicing Mutation in the Context of Therapy Related MDS

Virginia Olivia Volpe, MD, Najla Al Ali, M.Sc, Onyee Chan, MD, Eric Padron, MD, David A. Sallman, MD, Rami S. Komrokji, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-138833

Published: 2020

Journal Articles

Assessment of Cellworks Omics Biosimulation Therapy Response Predictions for Patients with Acute Myeloid Leukemia (AML) Using Cellworks Singula™: Mycare-020-01

Blood (2020) 136 (Supplement 1): 35.

https://doi.org/10.1182/blood-2020-142184

Published: 2020

Journal Articles

Identification of Pharmacogenomic Single Nucleotide Polymorphism Variants As Contributors to Toxicity Phenotype in the Treatment of Acute Childhood Leukemia

Trisha Larkin, MDMBA, Abdelrahman H Elsayed, MSc, Roya Rafiee, M.Sc., PhD, Natasha Emanuel, Beate Greer, Biljana N. Horn, MD, Jatinder K Lamba, MSc, PhD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-143195

Published: 2020

Journal Articles

AML Associated Mesenchymal Stroma Cells Support Growth of AML Cells As a Result of Activated Notch Signaling and This Can be Targeted By Dexamethasone

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-134177

Published: 2020

Journal Articles

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Agnieszka Wierzbowska, MDPhD, Agnieszka Pluta, MDPhD, Marta Antonina Libura, MDPhD, Anna Czyz, MDPhD, Sebastian Giebel, MDPhD, Piotr Stelmach, MDPhD, Magdalena Czemerska, MDPhD, Anna Kopinska, MD, Krzysztof Wozniczka, MDPhD, Grzegorz Helbig, MDPhD, Karol Wojcik, MD, Malgorzata Razny, MDPhD, Marta Sobas, MDPhD, Tomasz Wrobel, MDPhD, Andrzej Szczepaniak, MDPhD, Lidia Gil, MDPhD, Alicja Sadowska-Klasa, MD, Jan Zaucha, MDPhD, Tomasz Gromek, MDPhD, Marek Hus, MDPhD, Edyta Cichocka, MDPhD, Janusz Halka, MDPhD, Elzbieta Patkowska, Jolanta Wozniak, PhD, Agata Obara, MD, Beata Blajer-Olszewska, MD, Katarzyna Dulik, MD, Jerzy Holowiecki, MDPhD, Michal Soin, M.Sc., Tadeusz Robak, MDPhD, Nicole M. Cruz, MD, Nuria Mencia-Trinchant, PhD, Pinkal Desai, MDMPH, Sangmin Lee, MD, Michael B. Samuel, MD, Justin D. Kaner, MD, Ellen Ritchie, MD, Monica L. Guzman, PhD, Gail J. Roboz, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-140694

Published: 2020

Journal Articles

BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure

Dennis Dong Hwan Kim, MD, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Taehyung Kim, MSc, Eshetu G Atenafu, M.Sc., P.Stat, Donna L. Forrest, MD, Lynn Savoie, MD, Isabelle Bence-Bruckler, MD, Mary-Margaret Keating, MD FRCPC, Lambert Busque, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Kristjan Paulson, MD, Tracy L. Stockley, PhD FCCMG, FACMG, Pierre Laneuville, MD FRCPC, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-136162

Published: 2020

Journal Articles

Predicting Resistance to the Combination of ATO and ATRA in APL Patients with PML-Rara Fusions, Using a Computational Biology Modeling Approach: Mycare-021-01

Scott Howard, MD, Prashant Ramachandran Nair, B.Tech., Himanshu Grover, M.S., Anuj Tyagi, M.Sc., Pallavi Kumari, M.Sc., Samiksha Avinash Prasad, M.Sc., Upasana Mitra, M.Sc., Deepak Anil Lala, B.Tech., Humera Azam, M.Sc., Neha Gupta, M.Sc., Subrat Mohapatra, M.Sc., Poornachandra G, B.Tech., Nirjhar Mundkur, Michele Dundas Macpherson, B.A.Sc., Shweta Kapoor, M.Sc.

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-140617

Published: 2020

Journal Articles

Monosomy 7 and Co-Occurrent Genomic Aberrations Determine Chemotherapy Response in Acute Myeloid Leukemia (AML) Patients Using the Cellworks Omics Biology Model (CBM): Mycare-021-04

Blood (2020) 136 (Supplement 1): 9.

https://doi.org/10.1182/blood-2020-140087

Published: 2020

Journal Articles

Healthcare Utilization and Costs Associated with Different Treatment Protocols for Newly Diagnosed Childhood Acute Lymphoblastic Leukemia: A Population-Based Study

Sumit Gupta, MD, Nicole Mittman, PhD MSc, Petros Pechlivanoglou, M.Sc., PhD, Qing Li, MSc, Uma Athale, MD MBBS, MSc, Mylene Bassal, MD, Vicky R. Breakey, BSc,MDFRCPC, Paul J. Gibson, MD, Mariana Silva, MD FRCPC, Veda Zabih, Jason Pole, PhD, Rinku Sutradhar, PhD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-136365

Published: 2020

Journal Articles

Prediction of Clinical Response for Frontline Treatment of Acute Myeloid Leukemia (AML) Patients Using the Cellworks Omics Biology Model (CBM): Mycare-021-02

Michael Castro, MD, Prashant Ramachandran Nair, B.Tech., Himanshu Grover, M.S., Ansu Kumar, M.Sc., Ashish Agarwal, B.V.Sc., Rakhi Purushothaman Suseela, B.Tech., Reshma P Gopi, M.Sc., Naga Ganesh, B.Tech., Vijayashree P Shyamasundar, M.Sc., Shruthi Kulkarni, B.E., Mohammed Sauban, B.E., Ashokraja Balla, M.Tech., Srushti P Chafekar, M.Sc., Sayantani Roy Choudhury, M.Sc., Nirjhar Mundkur, Michele Dundas Macpherson, B.A.Sc., Shweta Kapoor, M.Sc., Scott Howard, MD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-141479

Published: 2020

Journal Articles

Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS)

Nathan Radakovich, BA, David A. Sallman, MD, Rena J. Buckstein, MD FRCPC, Andrew M. Brunner, MD, Sudipto Mukherjee, MD PhD MPH, Rami Komrokji, MD, Najla Al Ali, M.Sc, Jacob Shreve, MD MS, Yazan Rouphail, Cassandra M Kerr, MS, Yihong Guan, PhD, Teodora Kuzmanovic, BA, Metis Hasipek, PhD, Babal K. Jha, PhD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS, Aziz Nazha, MD

Blood (2020) 136 (Supplement 1): 54–55.

https://doi.org/10.1182/blood-2020-139815

Published: 2020

Journal Articles

Irs1 S57X Heterozygous Mutant Mice Display Normal Hematopoiesis and Phenotypic Features, While Homozygous Knockout Exhibit High Fetal or Postnatal Lethality

Bruna Alves Fenerich, BSc, Jaqueline Cristina Fernandes, BSc, MSc, Cleide Lúcia Araújo Silva, MSc, Juan L Coelho-Silva, BSc, MSc, Antonio Bruno Alves Silva, BSc, MSc, Natasha Peixoto Fonseca, B.Sc., M.Sc., João Agostinho Machado-Neto, PhD, Fabiola Traina, MD PhD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-139422

Published: 2020

NARROW

Superior Therapy Response Predictions for Patients with Myelodysplastic Syndrome (MDS) Using Cellworks Singula™: Mycare-020-02

Chromosomal Abnormalities in MDS Are Linked to Dysregulation of CDC20 and CEP55 Genes

Monoclonal Protein Response Trajectory and Survival in Newly Diagnosed Multiple Myeloma: A Retrospective Cohort Study

Efficient, Non-Viral and Reproducible Protocol for Stable Knockdown of Genes in Mantle Cell Lymphoma Cell Lines

Comparative Analysis for Differential Drug Response between Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) and T-Cell Acute Lymphoblastic Leukemia (T-ALL) Patients Using the Cellworks Omics Biology Model (CBM): Mycare-021-03

High MYC Protein Expression in MDS Is Associated with Early Transformation to AML

Detection of M-Protein in Acetonitrile Precipitates of Serum Using MALDI-TOF Mass Spectrometry: A Novel Methodology

Impact of Age, Comorbidity, and Polypharmacy on Treatment and Survival for Aggressive Non-Hodgkin Lymphoma

SF3B1 Splicing Mutation in the Context of Therapy Related MDS

Assessment of Cellworks Omics Biosimulation Therapy Response Predictions for Patients with Acute Myeloid Leukemia (AML) Using Cellworks Singula™: Mycare-020-01

Identification of Pharmacogenomic Single Nucleotide Polymorphism Variants As Contributors to Toxicity Phenotype in the Treatment of Acute Childhood Leukemia

AML Associated Mesenchymal Stroma Cells Support Growth of AML Cells As a Result of Activated Notch Signaling and This Can be Targeted By Dexamethasone

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure

Predicting Resistance to the Combination of ATO and ATRA in APL Patients with PML-Rara Fusions, Using a Computational Biology Modeling Approach: Mycare-021-01

Monosomy 7 and Co-Occurrent Genomic Aberrations Determine Chemotherapy Response in Acute Myeloid Leukemia (AML) Patients Using the Cellworks Omics Biology Model (CBM): Mycare-021-04

Healthcare Utilization and Costs Associated with Different Treatment Protocols for Newly Diagnosed Childhood Acute Lymphoblastic Leukemia: A Population-Based Study

Prediction of Clinical Response for Frontline Treatment of Acute Myeloid Leukemia (AML) Patients Using the Cellworks Omics Biology Model (CBM): Mycare-021-02

Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS)

Irs1 S57X Heterozygous Mutant Mice Display Normal Hematopoiesis and Phenotypic Features, While Homozygous Knockout Exhibit High Fetal or Postnatal Lethality

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only